pf-04518600

mAbexperimental

Clinical trial activity

8 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
6
Phase 3
1
Phase 4
0

Earliest trial started Apr 23, 2015 (NCT02315066)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • pf-04518600

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05059522Phase 3Sep 29, 2021Pfizer
NCT03971409Phase 2Jul 1, 2019Array BioPharma, Breast Cancer Research Foundation, Hoosier Cancer Research Network, Johns Hopkins University, Pfizer, Translational Breast Cancer Research Consortium, University of California, San Francisco
NCT03636503Phase 1Sep 30, 2018Harvard University, Pfizer
NCT03390296Phase 2Dec 27, 2017Pfizer, University of Texas at Houston
NCT03217747Phase 1/Phase 2 (Phase 2)Aug 2, 2017Pfizer, University of Texas at Houston
NCT03092856Phase 2Jul 10, 2017National Cancer Institute (NCI), University of Southern California
NCT02554812Phase 2Nov 1, 2015Pfizer
NCT02315066Phase 1Apr 23, 2015Pfizer
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit7332015
University of Texas at HoustonAcademic/Hospital2212017
Array BioPharmaFor profit1012019
Breast Cancer Research FoundationAcademic/Hospital1012019
Harvard UniversityAcademic/Hospital1112018
Hoosier Cancer Research NetworkAcademic/Hospital1012019
Johns Hopkins UniversityAcademic/Hospital1012019
National Cancer Institute (NCI)Government1012017
Translational Breast Cancer Research ConsortiumAcademic/Hospital1012019
University of California, San FranciscoAcademic/Hospital1112019
University of Southern CaliforniaAcademic/Hospital1112017
11 organizations
Page 1 / 1